drugset / Trial / NCT06013241
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Timeline
- Start
- 2023-10-30
- Primary completion
- 2025-09-30
- Completion
- 2025-10-30
Outcome
Missed primary endpoint
release “the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints” insmed.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brensocatib | Small molecule | 10 mg | Oral |
| Subject | Brensocatib | Small molecule | 40 mg | Oral |
| Background | Mometasone furoate | Other / unclassified | — | Intranasal |